AquaBounty Technologies, Inc., a biotechnology company, focuses on improving productivity in the commercial aquaculture industry in the United States and Canada.
AquaBounty Technologies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.88|
|52 Week High||US$3.52|
|52 Week Low||US$13.32|
|1 Month Change||-7.40%|
|3 Month Change||-22.56%|
|1 Year Change||-2.76%|
|3 Year Change||49.81%|
|5 Year Change||n/a|
|Change since IPO||-83.97%|
Recent News & Updates
AquaBounty Technologies' First Genetically Engineered Salmon On The Plate - Should You Join The Stream?
AquaBounty Technologies harvested their first batch of genetically engineered, or GE, salmon and it should be on the market soon. Reception of the GE salmon among consumers is going to be interesting and vital for the company's future; management execution level is key. Media coverage and headlines might be ahead; short-term turbulence in stock price is expected. AquaBounty is well funded and ready to continue its expansion.
Here's Why AquaBounty Technologies (NASDAQ:AQB) Can Manage Its Debt Despite Losing Money
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|AQB||US Biotechs||US Market|
Return vs Industry: AQB underperformed the US Biotechs industry which returned 17.8% over the past year.
Return vs Market: AQB underperformed the US Market which returned 33.4% over the past year.
Stable Share Price: AQB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: AQB's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
AquaBounty Technologies, Inc., a biotechnology company, focuses on improving productivity in the commercial aquaculture industry in the United States and Canada. It offers AquAdvantage Salmon, a bioengineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004.
AquaBounty Technologies Fundamentals Summary
|AQB fundamental statistics|
Is AQB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AQB income statement (TTM)|
|Cost of Revenue||US$8.20m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.27|
|Net Profit Margin||-4,564.01%|
How did AQB perform over the long term?See historical performance and comparison
Is AquaBounty Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AQB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AQB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AQB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: AQB is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AQB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AQB is good value based on its PB Ratio (1.3x) compared to the US Biotechs industry average (2.9x).
How is AquaBounty Technologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AQB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AQB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AQB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AQB's revenue (66% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: AQB's revenue (66% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AQB is forecast to be unprofitable in 3 years.
How has AquaBounty Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AQB is currently unprofitable.
Growing Profit Margin: AQB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AQB is unprofitable, and losses have increased over the past 5 years at a rate of 17% per year.
Accelerating Growth: Unable to compare AQB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AQB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: AQB has a negative Return on Equity (-8.45%), as it is currently unprofitable.
How is AquaBounty Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: AQB's short term assets ($208.0M) exceed its short term liabilities ($2.5M).
Long Term Liabilities: AQB's short term assets ($208.0M) exceed its long term liabilities ($9.0M).
Debt to Equity History and Analysis
Debt Level: AQB's debt to equity ratio (4.1%) is considered satisfactory.
Reducing Debt: AQB had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AQB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AQB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 11.8% each year
What is AquaBounty Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AQB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AQB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AQB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AQB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AQB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sylvia Wulf (63 yo)
Ms. Sylvia A. Wulf has been Chief Executive Officer, President and Executive Director of AquaBounty Technologies, Inc. since January 1, 2019. Ms. Wulf served as Senior Vice President and President of the M...
CEO Compensation Analysis
Compensation vs Market: Sylvia's total compensation ($USD534.71K) is below average for companies of similar size in the US market ($USD1.07M).
Compensation vs Earnings: Sylvia's compensation has been consistent with company performance over the past year.
Experienced Management: AQB's management team is considered experienced (2.3 years average tenure).
Experienced Board: AQB's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 58.1%.
AquaBounty Technologies, Inc.'s employee growth, exchange listings and data sources
- Name: AquaBounty Technologies, Inc.
- Ticker: AQB
- Exchange: NasdaqCM
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$275.580m
- Shares outstanding: 71.03m
- Website: https://www.aquabounty.com
Number of Employees
- AquaBounty Technologies, Inc.
- 2 Mill and Main Place
- Suite 395
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/27 23:01|
|End of Day Share Price||2021/10/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.